US6927044B2
(en)
*
|
1998-09-25 |
2005-08-09 |
Regeneron Pharmaceuticals, Inc. |
IL-1 receptor based cytokine traps
|
US20090137416A1
(en)
|
2001-01-16 |
2009-05-28 |
Regeneron Pharmaceuticals, Inc. |
Isolating Cells Expressing Secreted Proteins
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
WO2004100987A2
(fr)
*
|
2003-05-06 |
2004-11-25 |
Regeneron Pharmaceuticals, Inc. |
Procede d'utilisation d'antagonistes de l'il1 pour le traitement d'hyperplasie neointimale
|
SI3095793T1
(sl)
*
|
2003-07-28 |
2020-07-31 |
Genentech, Inc. |
Zmanjšanje izluževanja proteina A med afinitetno kromatografijo proteina A
|
US20050129685A1
(en)
*
|
2003-09-18 |
2005-06-16 |
Jingtai Cao |
Use of IL-1 blockers to prevent corneal inflammation and neovascularization
|
US20050165222A1
(en)
*
|
2003-10-15 |
2005-07-28 |
Applera Corporation |
Method of reducing leachate from protein a affinity media
|
AU2005219837A1
(en)
*
|
2004-02-27 |
2005-09-15 |
Regeneron Pharmaceuticals, Inc. |
IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
|
JP5022216B2
(ja)
*
|
2004-06-04 |
2012-09-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
自己炎症性疾患を処置するためのil−1アンタゴニストを使用する方法
|
US7572893B2
(en)
*
|
2004-08-17 |
2009-08-11 |
Regeneron Pharmaceuticals, Inc. |
IL-1 antagonist formulations
|
US7655758B2
(en)
|
2004-08-17 |
2010-02-02 |
Regeneron Pharmaceuticals, Inc. |
Stable liquid IL-1 antagonist formulations
|
EP2311871A3
(fr)
|
2004-08-17 |
2012-08-08 |
Regeneron Pharmaceuticals, Inc. |
Composition liquide stable comprenant des antagonistes de IL-1
|
US20060160737A1
(en)
*
|
2005-01-14 |
2006-07-20 |
Allen Radin |
Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis
|
US20060171948A1
(en)
*
|
2005-02-02 |
2006-08-03 |
Weinstein Steven P |
Methods of using IL-1 antagonists to reduce C-reactive protein
|
JP2009511545A
(ja)
*
|
2005-10-14 |
2009-03-19 |
ノボ・ノルデイスク・エー/エス |
Il−1インヒビターを使用する糖尿病の治療
|
CA2666629C
(fr)
*
|
2006-10-20 |
2016-08-16 |
Regeneron Pharmaceuticals, Inc. |
Utilisation d'antagonistes il-1 pour traiter la goutte ou la pseudo-goutte
|
US7632490B2
(en)
*
|
2006-10-20 |
2009-12-15 |
Regeneron Pharmaceuticals, Inc. |
Use of IL-1 antagonists to treat gout
|
WO2008093756A1
(fr)
*
|
2007-01-30 |
2008-08-07 |
Niigata University |
Préparation biologique
|
RU2473564C2
(ru)
|
2007-08-10 |
2013-01-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека с высокой аффинностью к фактору роста нервов человека
|
US10105441B2
(en)
*
|
2007-08-16 |
2018-10-23 |
The Schepens Eye Research Institute, Inc. |
Method for inhibiting or reducing dry eye disease by IL-1Ra
|
EP2620139B1
(fr)
|
2008-02-27 |
2016-07-20 |
Biomet Biologics, LLC |
Solutions riches d'un antagoniste du récepteur de l'interleukine-1
|
US8753690B2
(en)
*
|
2008-02-27 |
2014-06-17 |
Biomet Biologics, Llc |
Methods and compositions for delivering interleukin-1 receptor antagonist
|
US8828354B2
(en)
|
2008-03-27 |
2014-09-09 |
Warsaw Orthopedic, Inc. |
Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
|
US9132085B2
(en)
*
|
2008-04-18 |
2015-09-15 |
Warsaw Orthopedic, Inc. |
Compositions and methods for treating post-operative pain using clonidine and bupivacaine
|
US20090264489A1
(en)
*
|
2008-04-18 |
2009-10-22 |
Warsaw Orthopedic, Inc. |
Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
|
US8420114B2
(en)
*
|
2008-04-18 |
2013-04-16 |
Warsaw Orthopedic, Inc. |
Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
|
US8557273B2
(en)
|
2008-04-18 |
2013-10-15 |
Medtronic, Inc. |
Medical devices and methods including polymers having biologically active agents therein
|
USRE48948E1
(en)
|
2008-04-18 |
2022-03-01 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable polymer
|
US9125917B2
(en)
*
|
2008-04-18 |
2015-09-08 |
Warsaw Orthopedic, Inc. |
Fluocinolone formulations in a biodegradable polymer carrier
|
US8846068B2
(en)
|
2008-04-18 |
2014-09-30 |
Warsaw Orthopedic, Inc. |
Methods and compositions for treating post-operative pain comprising a local anesthetic
|
US9072727B2
(en)
|
2008-04-18 |
2015-07-07 |
Warsaw Orthopedic, Inc. |
Alpha adrenergic receptor agonists for treatment of degenerative disc disease
|
US20090264477A1
(en)
*
|
2008-04-18 |
2009-10-22 |
Warsaw Orthopedic, Inc., An Indiana Corporation |
Beta adrenergic receptor agonists for treatment of pain and/or inflammation
|
US8722079B2
(en)
|
2008-04-18 |
2014-05-13 |
Warsaw Orthopedic, Inc. |
Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
|
US8883768B2
(en)
*
|
2008-04-18 |
2014-11-11 |
Warsaw Orthopedic, Inc. |
Fluocinolone implants to protect against undesirable bone and cartilage destruction
|
US8956641B2
(en)
|
2008-04-18 |
2015-02-17 |
Warsaw Orthopedic, Inc. |
Alpha adrenergic receptor agonists for treatment of inflammatory diseases
|
US9132119B2
(en)
|
2008-04-18 |
2015-09-15 |
Medtronic, Inc. |
Clonidine formulation in a polyorthoester carrier
|
US8889173B2
(en)
|
2008-04-18 |
2014-11-18 |
Warsaw Orthopedic, Inc. |
Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
|
US20090263451A1
(en)
*
|
2008-04-18 |
2009-10-22 |
Warsaw Orthopedic, Inc. |
Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
|
US8629172B2
(en)
|
2008-04-18 |
2014-01-14 |
Warsaw Orthopedic, Inc. |
Methods and compositions for treating post-operative pain comprising clonidine
|
US20090263443A1
(en)
*
|
2008-04-18 |
2009-10-22 |
Warsaw Orthopedics, Inc. |
Methods for treating post-operative effects such as spasticity and shivering with clondine
|
US8956636B2
(en)
|
2008-04-18 |
2015-02-17 |
Warsaw Orthopedic, Inc. |
Methods and compositions for treating postoperative pain comprosing ketorolac
|
US9289409B2
(en)
*
|
2008-04-18 |
2016-03-22 |
Warsaw Orthopedic, Inc. |
Sulindac formulations in a biodegradable material
|
US20100015049A1
(en)
*
|
2008-07-16 |
2010-01-21 |
Warsaw Orthopedic, Inc. |
Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
|
US20100016265A1
(en)
*
|
2008-07-16 |
2010-01-21 |
Qaiser Yusuf |
Anti-inflammatory composition and method for preparation
|
US9492375B2
(en)
|
2008-07-23 |
2016-11-15 |
Warsaw Orthopedic, Inc. |
Foam carrier for bone grafting
|
BRPI0917554A2
(pt)
*
|
2008-08-01 |
2017-06-20 |
Axis Inc |
agente de tratamento ou agente de prevenção para oesteoartrite
|
US9161903B2
(en)
*
|
2008-10-31 |
2015-10-20 |
Warsaw Orthopedic, Inc. |
Flowable composition that hardens on delivery to a target tissue site beneath the skin
|
US10117906B2
(en)
*
|
2009-01-09 |
2018-11-06 |
The Schepens Eye Research Institute, Inc. |
Methods for reducing corneal nerves damage, corneal lymphangiogenesis or immunity to corneal antigens in dry-eye associated ocular surface diseases by IL-1Ra
|
US20100228097A1
(en)
*
|
2009-03-04 |
2010-09-09 |
Warsaw Orthopedic, Inc. |
Methods and compositions to diagnose pain
|
US20100226959A1
(en)
*
|
2009-03-04 |
2010-09-09 |
Warsaw Orthopedic, Inc. |
Matrix that prolongs growth factor release
|
US20100239632A1
(en)
|
2009-03-23 |
2010-09-23 |
Warsaw Orthopedic, Inc. |
Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
|
US8617583B2
(en)
|
2009-07-17 |
2013-12-31 |
Warsaw Orthopedic, Inc. |
Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
|
US8231891B2
(en)
|
2009-07-31 |
2012-07-31 |
Warsaw Orthopedic, Inc. |
Implantable drug depot for weight control
|
US20110052561A1
(en)
|
2009-08-27 |
2011-03-03 |
Biomet Biologics,LLC |
Osteolysis treatment
|
AU2010292486B2
(en)
|
2009-08-27 |
2014-08-07 |
Biomet Biologics, Llc |
Implantable device for production of interleukin-1 receptor antagonist
|
JP2013506687A
(ja)
|
2009-09-30 |
2013-02-28 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
|
US20110097375A1
(en)
|
2009-10-26 |
2011-04-28 |
Warsaw Orthopedic, Inc. |
Formulation for preventing or reducing bleeding at a surgical site
|
US20110097380A1
(en)
*
|
2009-10-28 |
2011-04-28 |
Warsaw Orthopedic, Inc. |
Clonidine formulations having antimicrobial properties
|
US9504698B2
(en)
*
|
2009-10-29 |
2016-11-29 |
Warsaw Orthopedic, Inc. |
Flowable composition that sets to a substantially non-flowable state
|
US8597192B2
(en)
|
2009-10-30 |
2013-12-03 |
Warsaw Orthopedic, Inc. |
Ultrasonic devices and methods to diagnose pain generators
|
US8758791B2
(en)
|
2010-01-26 |
2014-06-24 |
Warsaw Orthopedic, Inc. |
Highly compression resistant matrix with porous skeleton
|
US8475824B2
(en)
|
2010-01-26 |
2013-07-02 |
Warsaw Orthopedic, Inc. |
Resorbable matrix having elongated particles
|
US9486500B2
(en)
|
2010-01-28 |
2016-11-08 |
Warsaw Orthopedic, Inc. |
Osteoimplant and methods for making
|
US9050274B2
(en)
*
|
2010-01-28 |
2015-06-09 |
Warsaw Orthopedic, Inc. |
Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
|
US9125902B2
(en)
*
|
2010-01-28 |
2015-09-08 |
Warsaw Orthopedic, Inc. |
Methods for treating an intervertebral disc using local analgesics
|
JP2012246222A
(ja)
*
|
2010-01-29 |
2012-12-13 |
Axis Inc |
変形性関節症治療剤または予防剤を製造するための使用
|
JO3183B1
(ar)
|
2010-01-29 |
2018-03-08 |
Regeneron Pharma |
طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
|
EP2552967A4
(fr)
|
2010-04-02 |
2014-10-08 |
Amunix Operating Inc |
Protéines de fusion liantes, conjugués protéines de fusion liantes-médicaments, conjugués xten-médicaments et procédés pour les préparer et les utiliser
|
MX2013000301A
(es)
|
2010-07-09 |
2013-05-09 |
Biogen Idec Hemophilia Inc |
Factores quimericos de coagulacion.
|
EP2598526B1
(fr)
|
2010-07-29 |
2018-09-05 |
Eleven Biotherapeutics, Inc. |
Agonistes et antagonistes chimeriques du recepteur d'il-1 type i
|
US8246571B2
(en)
|
2010-08-24 |
2012-08-21 |
Warsaw Orthopedic, Inc. |
Drug storage and delivery device having a retaining member
|
WO2012030593A2
(fr)
|
2010-09-03 |
2012-03-08 |
Biomet Biologics, Llc |
Méthodes et compositions permettant d'administrer un antagoniste du récepteur de l'interleukine 1
|
US8404268B2
(en)
|
2010-10-26 |
2013-03-26 |
Kyphon Sarl |
Locally targeted anti-fibrotic agents and methods of use
|
US8740982B2
(en)
|
2010-10-26 |
2014-06-03 |
Kyphon Sarl |
Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
|
US9414930B2
(en)
|
2010-10-26 |
2016-08-16 |
Kyphon SÀRL |
Activatable devices containing a chemonucleolysis agent
|
JO3375B1
(ar)
|
2010-11-08 |
2019-03-13 |
Regeneron Pharma |
أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
|
WO2012075447A2
(fr)
|
2010-12-03 |
2012-06-07 |
Warsaw Orthopedic, Inc. |
Compositions et méthodes d'administration de clonidine et de bupivacaïne en direction d'un tissu cible
|
US9301946B2
(en)
|
2010-12-03 |
2016-04-05 |
Warsaw Orthopedic, Inc. |
Clonidine and GABA compounds in a biodegradable polymer carrier
|
US9060978B2
(en)
|
2011-01-24 |
2015-06-23 |
Warsaw Orthopedic, Inc. |
Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
|
US9717779B2
(en)
|
2011-01-31 |
2017-08-01 |
Warsaw Orthopedic, Inc. |
Implantable matrix having optimum ligand concentrations
|
CN103492416A
(zh)
|
2011-04-15 |
2014-01-01 |
默克专利股份公司 |
用于癌症中使用的抗il-1r1抑制剂
|
US9592243B2
(en)
|
2011-04-25 |
2017-03-14 |
Warsaw Orthopedic, Inc. |
Medical devices and methods comprising an anabolic agent for treatment of an injury
|
US9511077B2
(en)
|
2011-04-25 |
2016-12-06 |
Warsaw Orthopedic, Inc. |
Medical devices and methods comprising an anabolic agent for wound healing
|
US9205241B2
(en)
|
2011-07-12 |
2015-12-08 |
Warsaw Orthopedic, Inc. |
Medical devices and methods comprising an adhesive material
|
US9132194B2
(en)
|
2011-07-12 |
2015-09-15 |
Warsaw Orthopedic, Inc. |
Medical devices and methods comprising an adhesive sheet containing a drug depot
|
CA2855822C
(fr)
|
2011-11-14 |
2022-11-15 |
Regeneron Pharmaceuticals, Inc. |
Compositions et methodes permettant d'augmenter la masse et la force musculaires par un effet antagoniste specifiquement dirige contre la myostatine et/ou l'activine a
|
PT3384903T
(pt)
|
2011-11-18 |
2020-06-25 |
Regeneron Pharma |
Micropartícula contendo proteína terapêutica revestida com polímero biodegradável para uso médico
|
RS59670B1
(sr)
*
|
2012-01-12 |
2020-01-31 |
Bioverativ Therapeutics Inc |
Himerni polipeptidi faktora viii i njihove upotrebe
|
US9511018B2
(en)
|
2012-04-05 |
2016-12-06 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable matrix
|
US8735504B2
(en)
|
2012-05-02 |
2014-05-27 |
Warsaw Orthopedic, Inc. |
Methods for preparing polymers having low residual monomer content
|
CN103509100B
(zh)
*
|
2012-06-15 |
2017-10-27 |
上海百迈博制药有限公司 |
一种白细胞介素‑1受体拮抗剂突变体
|
EP3470432B1
(fr)
|
2012-08-21 |
2021-10-06 |
Sanofi Biotechnology |
Procédés de traitement ou de prévention de l'asthme par administration d'un antagoniste il-4r
|
JO3462B1
(ar)
|
2012-08-22 |
2020-07-05 |
Regeneron Pharma |
أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
|
WO2014035361A1
(fr)
*
|
2012-08-26 |
2014-03-06 |
R-PHARM, CJSC (Closed Joint Stock Company) |
Composition d'inhibiteur de l'il-1β et son utilisation
|
NZ731864A
(en)
|
2012-09-07 |
2022-07-01 |
Regeneron Pharma |
Methods for treating atopic dermatitis by administering an il-4r antagonist
|
TWI675044B
(zh)
|
2012-11-14 |
2019-10-21 |
美商再生元醫藥公司 |
重組細胞表面捕捉蛋白質
|
US9066853B2
(en)
|
2013-01-15 |
2015-06-30 |
Warsaw Orthopedic, Inc. |
Clonidine compounds in a biodegradable fiber
|
PL2956471T3
(pl)
|
2013-02-15 |
2024-06-24 |
R-Pharm International, Llc |
Kompozycja inhibitora il-1beta i jej zastosowanie
|
SG11201507447PA
(en)
|
2013-03-13 |
2015-10-29 |
Eleven Biotherapeutics Inc |
Chimeric cytokine formulations for ocular delivery
|
CA2902572A1
(fr)
|
2013-03-14 |
2014-10-02 |
Regeneron Pharmaceuticals, Inc. |
Anticorps humains diriges contre nav1.7
|
US9895418B2
(en)
|
2013-03-15 |
2018-02-20 |
Biomet Biologics, Llc |
Treatment of peripheral vascular disease using protein solutions
|
US20140271589A1
(en)
|
2013-03-15 |
2014-09-18 |
Biomet Biologics, Llc |
Treatment of collagen defects using protein solutions
|
US10143725B2
(en)
|
2013-03-15 |
2018-12-04 |
Biomet Biologics, Llc |
Treatment of pain using protein solutions
|
AU2014228938B2
(en)
|
2013-03-15 |
2019-05-02 |
Bioverativ Therapeutics Inc. |
Factor IX polypeptide formulations
|
US9950035B2
(en)
|
2013-03-15 |
2018-04-24 |
Biomet Biologics, Llc |
Methods and non-immunogenic compositions for treating inflammatory disorders
|
US9878011B2
(en)
|
2013-03-15 |
2018-01-30 |
Biomet Biologics, Llc |
Treatment of inflammatory respiratory disease using biological solutions
|
JP6456356B2
(ja)
|
2013-03-15 |
2019-01-23 |
ジェネンテック, インコーポレイテッド |
IL−22ポリペプチド及びIL−22Fc融合タンパク質並びに使用方法
|
US10208095B2
(en)
|
2013-03-15 |
2019-02-19 |
Biomet Manufacturing, Llc |
Methods for making cytokine compositions from tissues using non-centrifugal methods
|
US9758806B2
(en)
|
2013-03-15 |
2017-09-12 |
Biomet Biologics, Llc |
Acellular compositions for treating inflammatory disorders
|
CA2911547A1
(fr)
*
|
2013-05-31 |
2014-12-04 |
Regeneron Pharmaceuticals, Inc. |
Methodes d'utilisation d'antagonistes de l'il-1 pour traiter la maladie d'alzheimer
|
SG10201710557QA
(en)
|
2013-06-21 |
2018-01-30 |
Sanofi Biotechnology |
Methods for treating nasal polyposis by administering an il-4r antagonist
|
EP3074507B1
(fr)
|
2013-11-26 |
2022-01-05 |
Biomet Biologics, LLC |
Procédés de médiation des phénotypes macrophagiques
|
EP4382164A3
(fr)
|
2014-02-21 |
2024-08-07 |
Sanofi Biotechnology |
Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste de l'il-4r
|
US20210403534A1
(en)
*
|
2014-03-24 |
2021-12-30 |
R-Pharm Overseas, Inc. |
IL1-R1 DERIVED INHIBITOR OF IL-1b AND USE THEREOF
|
WO2015147789A1
(fr)
*
|
2014-03-24 |
2015-10-01 |
R-Pharm Overseas, Inc. |
Inhibiteur dérivé d'il1-r1 humain inhibitant il-1 b
|
US9775978B2
(en)
|
2014-07-25 |
2017-10-03 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having a retaining member
|
US10080877B2
(en)
|
2014-07-25 |
2018-09-25 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having a drug cartridge
|
US10441635B2
(en)
|
2014-11-10 |
2019-10-15 |
Biomet Biologics, Llc |
Methods of treating pain using protein solutions
|
IL303337A
(en)
|
2014-11-14 |
2023-08-01 |
Regeneron Pharma |
Methods for the treatment of chronic sinusitis with nasal polyps by adding an R4–IL antagonist
|
DK3253875T3
(da)
|
2015-02-04 |
2020-04-14 |
H Hoffmann La Roche Ag |
Tau-antisense-oligomerer og anvendelser deraf
|
EP3954993A1
(fr)
|
2015-02-04 |
2022-02-16 |
Bristol-Myers Squibb Company |
Procédés de sélection de molécules thérapeutiques
|
WO2016139543A1
(fr)
*
|
2015-03-01 |
2016-09-09 |
Arjun Jain |
Récepteur d'endothéline-1 sur la base d'éponge d'endothéline-1
|
GB201503453D0
(en)
|
2015-03-01 |
2015-04-15 |
Jain Arjun |
Endothelin-1"sponge"
|
US9763800B2
(en)
|
2015-03-18 |
2017-09-19 |
Biomet C. V. |
Implant configured for hammertoe and small bone fixation
|
EP3280435B1
(fr)
|
2015-04-06 |
2021-06-02 |
Acceleron Pharma Inc. |
Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
KR20170135967A
(ko)
|
2015-04-15 |
2017-12-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법
|
US10076650B2
(en)
|
2015-11-23 |
2018-09-18 |
Warsaw Orthopedic, Inc. |
Enhanced stylet for drug depot injector
|
DK3389636T3
(da)
|
2015-12-16 |
2022-09-19 |
Regeneron Pharma |
Sammensætninger og fremgangsmåder til fremstilling af proteinmikropartikler
|
US10549081B2
(en)
|
2016-06-23 |
2020-02-04 |
Warsaw Orthopedic, Inc. |
Drug delivery device and methods having a retaining member
|
WO2018035470A1
(fr)
|
2016-08-18 |
2018-02-22 |
Regeneron Pharmaceuticals, Inc. |
Test de détermination du potentiel d'auto-association d'une protéine utilisant la spectroscopie de nanoparticules à auto-interaction dépendante de la concentration
|
EP3506931B1
(fr)
|
2016-09-01 |
2024-07-31 |
Regeneron Pharmaceuticals, Inc. |
Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r
|
MA46472A
(fr)
|
2016-10-05 |
2019-08-14 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
WO2018068012A1
(fr)
|
2016-10-07 |
2018-04-12 |
Regeneron Pharmaceuticals, Inc. |
Protéine lyophilisée stable à la température ambiante
|
US10434261B2
(en)
|
2016-11-08 |
2019-10-08 |
Warsaw Orthopedic, Inc. |
Drug pellet delivery system and method
|
IL266640B
(en)
|
2016-11-29 |
2022-09-01 |
Regeneron Pharma |
A pharmaceutical preparation for the prevention of opioid addiction
|
TWI784988B
(zh)
|
2016-12-01 |
2022-12-01 |
美商再生元醫藥公司 |
治療發炎症狀的方法
|
WO2019018441A1
(fr)
*
|
2017-07-17 |
2019-01-24 |
Massachusetts Institute Of Technology |
Atlas de cellules de tissus barrières sains et malades
|
MX2020004467A
(es)
|
2017-10-30 |
2020-10-22 |
Sanofi Biotechnology |
Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
|
KR20200128125A
(ko)
|
2018-03-01 |
2020-11-11 |
리제너론 파아마슈티컬스, 인크. |
신체 조성을 변경하기 위한 방법
|
BR112020022164A2
(pt)
|
2018-05-18 |
2021-02-02 |
Bioverativ Therapeutics Inc. |
métodos de tratamento de hemofilia a
|
CN112839956A
(zh)
|
2018-08-10 |
2021-05-25 |
瑞泽恩制药公司 |
安全有效治疗膝和/或髋疼痛的药物组合物
|
BR112021018627A2
(pt)
|
2019-03-21 |
2021-11-23 |
Regeneron Pharma |
Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
|
WO2020223541A1
(fr)
|
2019-05-01 |
2020-11-05 |
Sanofi Biotechnology |
Méthodes de traitement ou de prévention de l'asthme par administration d'un antagoniste d'il-33
|
AU2020315369A1
(en)
|
2019-07-16 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating or preventing asthma by administering an IL-4R antagonist
|
BR112022010934A2
(pt)
|
2019-12-06 |
2022-11-29 |
Sanofi Biotechnology |
Métodos para tratar copd administrando um antagonista de il-33
|
CA3162507A1
(fr)
|
2019-12-23 |
2021-07-01 |
Helene Goulaouic |
Methodes de traitement ou de prevention de l'asthme allergique par administration d'un antagoniste d'il-33 et/ou d'un antagoniste d'il-4r
|
CA3174332A1
(fr)
|
2020-04-21 |
2021-10-28 |
Jason PERERA |
Profilage tcr/bcr
|
KR20230082650A
(ko)
|
2020-10-05 |
2023-06-08 |
사노피 바이오테크놀로지 |
Il-4r 길항제를 투여하여 소아 대상체에서 천식을 치료하는 방법
|
AU2021385363A1
(en)
|
2020-11-25 |
2023-06-08 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
TW202233827A
(zh)
|
2021-01-20 |
2022-09-01 |
美商再生元醫藥公司 |
改良細胞培養中蛋白質效價的方法
|
US20220404369A1
(en)
|
2021-03-03 |
2022-12-22 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for quantifying and modifying protein viscosity
|
MX2023014246A
(es)
|
2021-06-01 |
2024-01-17 |
Regeneron Pharma |
Ensayos y reactivos de microchips de electroforesis capilar.
|
AU2022316939A1
(en)
|
2021-07-26 |
2024-03-07 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist
|
WO2023039457A1
(fr)
|
2021-09-08 |
2023-03-16 |
Regeneron Pharmaceuticals, Inc. |
Procédé à haut rendement et fondé sur la spectrométrie de masse pour quantifier des anticorps et d'autres protéines contenant fc
|
IL312187A
(en)
|
2021-10-20 |
2024-06-01 |
Regeneron Pharma |
Methods for treating prurigo nodularis by administering an IL-4R antagonist
|
WO2023076340A1
(fr)
|
2021-10-26 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Systèmes et procédés de génération d'eau de laboratoire et de distribution d'eau de laboratoire à différentes températures
|
WO2023092052A1
(fr)
|
2021-11-19 |
2023-05-25 |
Regeneron Pharmaceuticals, Inc. |
Méthodes et compositions pour réduire la douleur centralisée
|
WO2023169686A1
(fr)
|
2022-03-10 |
2023-09-14 |
Buzzard Pharmaceuticals AB |
Inhibiteur du récepteur de l'interleukine-1 de type 1 destiné à être utilisé dans le traitement du cancer
|
WO2023212586A1
(fr)
|
2022-04-27 |
2023-11-02 |
Regeneron Pharmaceuticals, Inc. |
Procédés de sélection de patients pour le traitement avec un antagoniste du ngf
|
WO2024047021A1
(fr)
|
2022-08-29 |
2024-03-07 |
Sanofi |
Méthodes de traitement de l'urticaire au froid inductible chronique par administration d'un antagoniste de l'il-4r
|
WO2024158961A1
(fr)
|
2023-01-25 |
2024-08-02 |
Regeneron Pharmaceuticals, Inc. |
Caractérisation basée sur la spectrométrie de masse d'anticorps co-exprimés in vivo
|
US20240255519A1
(en)
|
2023-02-01 |
2024-08-01 |
Regeneron Pharmaceuticals, Inc. |
Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
|
WO2024178213A2
(fr)
|
2023-02-22 |
2024-08-29 |
Regeneron Pharmaceuticals, Inc. |
Paramètres d'adéquation de système et vieillissement de colonne
|